BIRO Report site: rrdmcentre2 , 01 April 2009
Timeframe: 11688 - 12052
Demographic characteristics
1.1. Age (Classes)
Clinical characteristics
2.1 Diabetes Status
2.1.1. Type of diabetes
2.1.2. Duration of diabetes (Classes)
2.2 Risk Factors
2.2.1 Obesity
2.2.1.1. Weight (last episode in 12 months)
2.2.1.2. BMI (last episode in 12 months)
2.2.2 Lifestyle
2.2.2.1 Smoking status (last episode in 12 months)
2.2.3. Clinical measurements
2.2.3.1. Systolic BP (last episode in 12 months)
2.2.3.2. Diastolic BP (last episode in 12 months)
2.2.3.3. Total cholesterol (last episode in 12 months)
2.2.3.4. HDL-cholesterol (last episode in 12 months)
2.2.3.5. Creatinine (last episode in 12 months)
2.2.3.6. HbA1c (last episode in 12 months)
2.3. Diabetes complications
2.3.1. Retinopathy (first episode in 12 months)
2.3.2. End stage renal failure (first episode in 12 months)
2.3.3. Foot ulcer (first episode in 12 months)
2.3.4. Amputation (first episode in 12 months)
2.3.5. Stroke (first episode in 12 months)
2.3.6. Myocardal infarction (first episode in 12 months)
2.3.7. Hypertension (first episode in 12 months)
Health System
3.1. Structure (provider level)
3.1.1 Type of Provider
3.1.2 Average diabetes population per center
3.2. Structural quality
3.2.1 Hospital beds per 100,000 population
3.2.2 Physicians employed per 100,000 population
3.3. Processes (individual level)
3.3.1. Foot examination
3.3.1.1 Done (last episode in 12 months)
3.3.2. Eye examination
3.3.2.1 Done (last episode in 12 months)
3.3.3. Measurements done
3.3.3.1 BP (last episode in 12 months)
3.3.3.2 Lipids
3.3.3.3 Microalbumin (last episode in 12 months)
3.3.3.4 HbA1c (last episode in 12 months)
3.3.4 Treatment
3.3.4.1 Antihypertensive Medication (last episode in 12 months)
3.3.4.2 Lipid Lowering Medication (last episode in 12 months)
3.3.4.3 ASA Medication (last episode in 12 months)
3.3.4.4.1 Glucose Lowering: Diet Only (last episode in 12 months)
3.3.4.4.2 Glucose Lowering: Tablets Only (last episode in 12 months)
3.3.4.4.3 Glucose Lowering: Insulin Only (last episode in 12 months)
3.3.4.4.4 Glucose Lowering: Insulin and Tablets (last episode in 12 months)
3.3.4.4.5 Glucose Lowering: Insulin Pump (last episode in 12 months)
3.3.5 Management
3.3.5.1 Self monitoring
3.3.5.2 Visit Frequency
Population
4.1.1 Total Population
4.1.2 Life expectancy
4.1.3 Mortality Data
Risk Adjusted Indicators
5.1. Epidemiology
5.1.1 Prevalence of diabetes mellitus per 1,000
5.1.2. Age at diagnosis by 10 year age bands (incidence)
5.2. Process Quality
5.2.1 Percentage of patients with one or more HbA1c tests during the last 12 months
5.2.2 Percentage of patients with at least one test for microalbuminuria during the last 12 months
5.2.3 Percentage of diabetes patients who received a dilated eye examination or evaluation of retinal photography by a trained caregiver within the last 12 months
5.2.4 Percentage of diabetes patients receiving at least one foot examination within the last 12 months
5.2.5 Percentage of diabetes patients whose smoking status was ascertained and documented within the last 12 months
5.2.6 Percent with serum creatinine tested in last 12 months
5.2.7 Percentage of patients with diabetes and one or more blood pressure measurements within the last 12 months
5.2.8 Percentage of patients with hypertension who receive antihypertensive medication
5.2.9 Type of oral therapy (distribution of agents) in patients with diabetes type 2
5.2.10 Portion of patients treated with insulin among patients with diabetes
5.2.11 Portion of patients treated with insulin in combination with OADs among patients with diabetes
5.2.12 Percentage of insulin treated patients with pump therapy
5.2.13 Portion of diabetes patients with anti hypertensive treatment
5.2.14 Portion of diabetes patients with lipid lowering treatment
5.2.15 Portion of diabetes patients with ASA treatment
5.2.16 Percent of patients with diabetes performing selfmonitoring of blood glucose/ urine testing
5.3. Outcome quality - intermediate outcomes
5.3.1 Percentage of patients with most recent HbA1c level greater than 9.0 pct (poor control)
5.3.2 Percentage of patients with most recent HbA1c level greater than 7,5 pct
5.3.3 Percentage of patients with most recent blood pressure less than 140/90 mmHg
5.3.4 Percentage of patients with BMI greater than 30
5.3.5 Percentage with microalbuminuria in last 12 months (among those who have been tested)
5.3.6 Rate of current smokers among diabetes patients
5.3.7 Former or current foot ulceration
5.4. Outcome quality - terminal outcomes
5.4.1 Annual incidence of dialysis and/or transplantation (renal replacement therapy in patients with diabetes
5.4.2 ESRF in Persons with Diabetes